相关数据集
Fig8
Schematic illustration of eNK-EXO enhance the anti-tumor effects against ovarian cancer by delivering chemotherapeutic drugs and reactivating NK cell functions
NIAID Data Ecosystem80
Complete list of synlet interactions addressed by novel drug combinations.
The full list of addressed synlet interactions as well as the respective novel proposed drug combinations are given in the S1 Table. Synlet interactions are sorted in descending order based on the sum
NIAID Data Ecosystem50
Table_1_A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy.DOCX
Background: Epithelial ovarian cancer (EOC) is the leading cause of gynecological cancer-related deaths worldwide. Preclinical studies found that copper-lowering agents could re-sensitize platinum-res
NIAID Data Ecosystem30
Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer
We examined the transcriptional changes modulated by ESR2 agonist liquiritigenin by perfroming global transcriptome analysis. ES2 cells were treated with either vehicle or liquiritigenin for 24 h and
NIAID Data Ecosystem60
ARID1A-mutated ovarian cancers depend on HDAC6 activity
ARID1A, encoding a subunit of the SWI/SNF chromatin remodeling complex, is the most mutated epigenetic regulator in human cancers. ARID1A and TP53 mutations are typically mutually exclusive. Therap
NIAID Data Ecosystem40
